YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention

por Davies, Alastair H., Dunn, Sandra E.
Publicado em 2011

Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells

por Hu, Kaiji, Law, Jennifer H, Fotovati, Abbas, Dunn, Sandra E
Publicado em 2012

YB-1 is a Transcription/Translation Factor that Orchestrates the Oncogenome by Hardwiring Signal Transduction to Gene Expression

por Wu, Joyce, Stratford, Anna L., Astanehe, Arezoo, Dunn, Sandra E.
Publicado em 2007

Interplay between YB-1 and IL-6 promotes the metastatic phenotype in breast cancer cells

por Castellana, Bàrbara, Aasen, Trond, Moreno-Bueno, Gema, Dunn, Sandra E., Ramón y Cajal, Santiago
Publicado no Oncotarget (2015)

Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells

por Davies, Alastair H., Reipas, Kristen, Hu, Kaiji, Berns, Rachel, Firmino, Natalie, Stratford, Anna L., Dunn, Sandra E.
Publicado no Oncotarget (2015)

Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK)

por Santos, Nancy Dos, Habibi, Golareh, Wang, Michelle, Law, Jennifer H., Andrews, Heather N., Wei, Daniel, Triche, Timothy, Dedhar, Shoukat, Dunn, Sandra E.
Publicado em 2007

Deep Sequencing Identifies IDH1 R132S Mutation in Adult Medulloblastoma

por Snuderl, Matija, Triscott, Joanna, Northcott, Paul A., Shih, Helen A., Kong, Esther, Robinson, Hayley, Dunn, Sandra E., Iafrate, A. John, Yip, Stephen
Publicado no J Clin Oncol (2015)

Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes

por Habibi, Golareh, Leung, Samuel, Law, Jennifer H, Gelmon, Karen, Masoudi, Hamid, Turbin, Dmitry, Pollak, Michael, Nielsen, Torsten O, Huntsman, David, Dunn, Sandra E
Publicado em 2008

Identification of ROCK1 kinase as a critical regulator of Beclin1 mediated autophagy during metabolic stress

por Gurkar, Aditi U., Chu, Kiki, Raj, Lakshmi, Bouley, Richard, Lee, Seung-Hwan, Kim, Young-Bum, Dunn, Sandra E., Mandinova, Anna, Lee, Sam W.
Publicado em 2013

Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer

por Panupinthu, Nattapon, Yu, Shuangxing, Zhang, Dong, Zhang, Fan, Gagae, Mihai, Lu, Yiling, Grandis, Jennifer R., Dunn, Sandra E., Lee, Hoi Young, Mills, Gordon B.
Publicado em 2013

Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours

por Kucab, Jill E, Lee, Cathy, Chen, Ching-Shih, Zhu, Jiuxiang, Gilks, C Blake, Cheang, Maggie, Huntsman, David, Yorida, Erika, Emerman, Joanne, Pollak, Michael, Dunn, Sandra E
Publicado em 2005

Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer

por Dahl, Edgar, En-Nia, Abdelaziz, Wiesmann, Frank, Krings, Renate, Djudjaj, Sonja, Breuer, Elisabeth, Fuchs, Thomas, Wild, Peter J, Hartmann, Arndt, Dunn, Sandra E, Mertens, Peter R
Publicado em 2009

Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells

por Stratford, Anna L, Fry, Christopher J, Desilets, Curtis, Davies, Alastair H, Cho, Yong Y, Li, Yvonne, Dong, Zigang, Berquin, Isabelle M, Roux, Philippe P, Dunn, Sandra E
Publicado em 2008

siRNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas

por Hu, Kaiji, Lee, Cathy, Qiu, Dexin, Fotovati, Abbas, Davies, Alastair, Abu-Ali, Samah, Wai, Daniel, Lawlor, Elizabeth R., Triche, Timothy J., Pallen, Catherine J., Dunn, Sandra E.
Publicado em 2009

Molecular Decoy to the Y-Box Binding Protein-1 Suppresses the Growth of Breast and Prostate Cancer Cells whilst Sparing Normal Cell Viability

por Law, Jennifer H., Li, Yvonne, To, Karen, Wang, Michelle, Astanehe, Arezoo, Lambie, Karen, Dhillon, Jaspreet, Jones, Steven J. M., Gleave, Martin E., Eaves, Connie J., Dunn, Sandra E.
Publicado em 2010

YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction, and HER2 amplification

por Davies, Alastair H., Barrett, Irene, Pambid, Mary Rose, Hu, Kaiji, Stratford, Anna L., Freeman, Spencer, Berquin, Isabelle M., Pelech, Steven, Hieter, Philip, Maxwell, Christopher, Dunn, Sandra E.
Publicado em 2011

Disulfiram, a drug widely used to control alcoholism, suppresses self-renewal of glioblastoma and overrides resistance to temozolomide

por Triscott, Joanna, Lee, Cathy, Hu, Kaiji, Fotovati, Abbas, Berns, Rachel, Pambid, Mary, Luk, Margaret, Kast, Richard E., Kong, Esther, Toyota, Eric, Yip, Stephen, Toyota, Brian, Dunn, Sandra E.
Publicado em 2012

Y-box-binding protein 1 contributes to IL-7-mediated survival signaling in B-cell precursor acute lymphoblastic leukemia

por Kariminia, Amina, Ivison, Sabine M., Leung, Vivian M., Sung, Susanna, Couto, Nicole, Rozmus, Jacob, Rolf, Nina, Narendran, Aru, Dunn, Sandra E., Reid, Gregor S.D., Schultz, Kirk R.
Publicado no Oncol Lett (2017)

Anti-CD13 antibodies in children with extensive chronic graft-versus-host disease and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Childr...

por Cuvelier, Geoff D.E., Kariminia, Amina, Fujii, Hisaki, Aslanian, Soudabeh, Wall, Donna, Goldman, Fred, Grupp, Stephan A., Dunn, Sandra E., Krailo, Mark, Shapiro, Linda H., Gilman, Andrew, Schultz, Kirk R.
Publicado em 2010

Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1)

por Reipas, Kristen M., Law, Jennifer H., Couto, Nicole, Islam, Sumaiya, Li, Yvonne, Li, Huifang, Cherkasov, Artem, Jung, Karen, Cheema, Amarpal S., Jones, Steven J.M., Hassell, John A., Dunn, Sandra E.
Publicado em 2013